| Pair Name | Triptolide, Cetuximab | ||
| Phytochemical Name | Triptolide (PubChem CID: 107985 ) | ||
| Anticancer drug Name | Cetuximab (PubChem CID: / ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Drug Name | Cetuximab |
| Adverse Reactions | Acne-like rash, itchy skin. This was inferred hot nature anticancer drug. |
| Recommendations | Cold: Tripterygium wilfordii |
| Reference | Malignant tumors in the era of immunotherapy based on traditional Chinese medicine's "cold and hot theory" Construction of integrated traditional Chinese and Western medicine treatment paradigm[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine,2023,32(12):1712-1716. DOI:10.3969/j.issn.1008-8849.2023.12.022. ref_link |
| Pair Name | Triptolide, Cetuximab | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | EGFR | hsa1956 |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 | |
| NCI-H520 | Lung squamous cell carcinoma | Homo sapiens (Human) | CVCL_1566 | |
| UM-SCC-6 | Tongue squamous cell carcinoma | Homo sapiens (Human) | CVCL_7773 | |
| In Vivo Model | To establish xenografts of cancer cell lines, a suspension of 5×10⁶ H1299, UM-SCC6 cancer cells in 0.1 mL RPMI 1640 was injected into the subcutaneous dorsa of mice at the proximal midline. | |||
| Result | Cet-TPL represents a potent targeting therapeutic agent against EGFR-overexpressing NSCLC and others. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II. Mol Ther Oncolytics. 2020 Jul 6;18:304-316. doi: 10.1016/j.omto.2020.07.001. | Click |
